Les progrès dans le traitement des cancers de la thyroide à l'ère des thérapies ciblées moléculaires

G. Malouf; E. Baudin; J. C. Soria; M. Schlumberger

doi:10.1684/bdc.2008.0798

Les progrès dans le traitement des cancers de la thyroide à l'ère des thérapies ciblées moléculaires

Translated title of the contribution: Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies

G. Malouf, E. Baudin, J. C. Soria, M. Schlumberger

Research output: Contribution to journal › Review article › peer-review

5 Citations (Scopus)

Abstract

During last decade, many progresses have been made in the understanding of thyroid cancer molecular biology. This knowledge led to the development of novel targeted therapy in iodine-resistant patients. However, the management of patients remains complex because of the broad spectrum of clinical presentation of thyroid cancers, differences in their natural histories and the lack of data about randomized trials. Angiogenesis inhibitors (sorafenib, motesanib, axitinib and vandetanib) have shown promising activity in differentiated thyroid cancer. Vandetanib, an inhibitor of RET and VEGFR tyrosine-kinases, is promising in medullary thyroid cancers. Preliminary results of these trials are discussed in this review.

Translated title of the contribution	Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies
Original language	French
Pages (from-to)	95-101
Number of pages	7
Journal	Bulletin du Cancer
Volume	96
Issue number	1
DOIs	https://doi.org/10.1684/bdc.2008.0798
Publication status	Published - 1 Jan 2009

Access to Document

10.1684/bdc.2008.0798

Cite this

@article{097a743b408444a6a51ee6c885bc2979,

title = "Les progr{\`e}s dans le traitement des cancers de la thyroide {\`a} l'{\`e}re des th{\'e}rapies cibl{\'e}es mol{\'e}culaires",

abstract = "During last decade, many progresses have been made in the understanding of thyroid cancer molecular biology. This knowledge led to the development of novel targeted therapy in iodine-resistant patients. However, the management of patients remains complex because of the broad spectrum of clinical presentation of thyroid cancers, differences in their natural histories and the lack of data about randomized trials. Angiogenesis inhibitors (sorafenib, motesanib, axitinib and vandetanib) have shown promising activity in differentiated thyroid cancer. Vandetanib, an inhibitor of RET and VEGFR tyrosine-kinases, is promising in medullary thyroid cancers. Preliminary results of these trials are discussed in this review.",

keywords = "Angiogenesis inhibitors, Medullary thyroid cancers, Molecular biology, Targeted therapies, Thyroid cancers, Tyrosine kinases inhibitors",

author = "G. Malouf and E. Baudin and Soria, {J. C.} and M. Schlumberger",

year = "2009",

month = jan,

day = "1",

doi = "10.1684/bdc.2008.0798",

language = "Fran{\c c}ais",

volume = "96",

pages = "95--101",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "1",

}

TY - JOUR

T1 - Les progrès dans le traitement des cancers de la thyroide à l'ère des thérapies ciblées moléculaires

AU - Malouf, G.

AU - Baudin, E.

AU - Soria, J. C.

AU - Schlumberger, M.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - During last decade, many progresses have been made in the understanding of thyroid cancer molecular biology. This knowledge led to the development of novel targeted therapy in iodine-resistant patients. However, the management of patients remains complex because of the broad spectrum of clinical presentation of thyroid cancers, differences in their natural histories and the lack of data about randomized trials. Angiogenesis inhibitors (sorafenib, motesanib, axitinib and vandetanib) have shown promising activity in differentiated thyroid cancer. Vandetanib, an inhibitor of RET and VEGFR tyrosine-kinases, is promising in medullary thyroid cancers. Preliminary results of these trials are discussed in this review.

AB - During last decade, many progresses have been made in the understanding of thyroid cancer molecular biology. This knowledge led to the development of novel targeted therapy in iodine-resistant patients. However, the management of patients remains complex because of the broad spectrum of clinical presentation of thyroid cancers, differences in their natural histories and the lack of data about randomized trials. Angiogenesis inhibitors (sorafenib, motesanib, axitinib and vandetanib) have shown promising activity in differentiated thyroid cancer. Vandetanib, an inhibitor of RET and VEGFR tyrosine-kinases, is promising in medullary thyroid cancers. Preliminary results of these trials are discussed in this review.

KW - Angiogenesis inhibitors

KW - Medullary thyroid cancers

KW - Molecular biology

KW - Targeted therapies

KW - Thyroid cancers

KW - Tyrosine kinases inhibitors

UR - http://www.scopus.com/inward/record.url?scp=61549090221&partnerID=8YFLogxK

U2 - 10.1684/bdc.2008.0798

DO - 10.1684/bdc.2008.0798

M3 - Article 'review'

C2 - 19211364

AN - SCOPUS:61549090221

SN - 0007-4551

VL - 96

SP - 95

EP - 101

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - 1

ER -

Les progrès dans le traitement des cancers de la thyroide à l'ère des thérapies ciblées moléculaires

Abstract

Access to Document

Other files and links

Cite this